Abstract
Receptors of glutamic acid are known for over 30 years for their action and for about 20 years for their structure. Presence of at least three classes of ionotropic receptors was confirmed at the beginning of 80’. Recognition of the sequence and first cloning were done at the beginning of 90’. In 1994 ligand binding site was recognized at the junction of two subunits S1-S2 in the ligand-binding domain.
Since then, many subtypes of ionotropic and metabotropic glutamate receptors were recognized, together with their localization and functions.
In the meantime numerous orthosteric ligands, both agonists and antagonists were developed especially for NMDA ion channels. Their usefulness as drugs was rather low, due to the involvement in the excitatory tract. More interest was focused on metabotropic receptors, which are GPSR’s and can be modulated both by orthosteric and allosteric modulators.
It seems like allosterism could be considered as promising future for glutamate receptors and ion channels, especially when first allosteric negative modulators of the mGluR2 went close into the clinical trial.
Keywords: iGluR, mGluR, NMDA, AMPA, KA, AMPA auxiliary proteins, allosteric mGluR PAM and NAM modulators.
Anti-Cancer Agents in Medicinal Chemistry
Title:Potential Future of New Glutamate Agonists and Antagonists Development
Volume: 18 Issue: 4
Author(s): Dariusz Matosiuk*
Affiliation:
- Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University, Chodzki 4A, 20-093 Lublin,Poland
Keywords: iGluR, mGluR, NMDA, AMPA, KA, AMPA auxiliary proteins, allosteric mGluR PAM and NAM modulators.
Abstract: Receptors of glutamic acid are known for over 30 years for their action and for about 20 years for their structure. Presence of at least three classes of ionotropic receptors was confirmed at the beginning of 80’. Recognition of the sequence and first cloning were done at the beginning of 90’. In 1994 ligand binding site was recognized at the junction of two subunits S1-S2 in the ligand-binding domain.
Since then, many subtypes of ionotropic and metabotropic glutamate receptors were recognized, together with their localization and functions.
In the meantime numerous orthosteric ligands, both agonists and antagonists were developed especially for NMDA ion channels. Their usefulness as drugs was rather low, due to the involvement in the excitatory tract. More interest was focused on metabotropic receptors, which are GPSR’s and can be modulated both by orthosteric and allosteric modulators.
It seems like allosterism could be considered as promising future for glutamate receptors and ion channels, especially when first allosteric negative modulators of the mGluR2 went close into the clinical trial.
Export Options
About this article
Cite this article as:
Matosiuk Dariusz *, Potential Future of New Glutamate Agonists and Antagonists Development, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (4) . https://dx.doi.org/10.2174/1871520618666180404125041
DOI https://dx.doi.org/10.2174/1871520618666180404125041 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Traces of Sound: Taking the Road to Skin
Current Rheumatology Reviews Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Current Pharmaceutical Design The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics Design, Synthesis and Cytotoxicity of Novel Coumarin-1,2,3-triazole-1,2,4- Oxadiazole Hybrids as Potent Anti-breast Cancer Agents
Letters in Drug Design & Discovery Biocompatible Europium Doped Hydroxyapatite Nanoparticles as a Biological Fluorescent Probe
Current Nanoscience Isoform-Specific Role of Akt Kinase in Cancer and its Selective Targeting by Potential Anticancer Natural Agents
The Natural Products Journal Targeting Protein Multiple Conformations: A Structure-Based Strategy for Kinase Drug Design
Current Topics in Medicinal Chemistry COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics The Effects of β-glucans on Cancer Metastasis
Anti-Cancer Agents in Medicinal Chemistry Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Anticancer Activities and Mechanisms of Bisdioxopiperazine Compounds Probimane and MST-16
Anti-Cancer Agents in Medicinal Chemistry Predictive Role of Gene Polymorphisms Affecting Thrombin-Generation Pathway in Variable Efficacy of Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Recent Patents on DNA & Gene Sequences The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Homeobox Genes and Human Genetic Disorders
Current Molecular Medicine Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Dendritic Cell-Based Immune Therapy in Liver Diseases
Current Immunology Reviews (Discontinued)